Endovascular treatment of unruptured intracranial aneurysms (UIAs) commonly requires dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to reduce thromboembolic risk related to stents and intravascular devices. Clopidogrel remains widely used but exhibits variable bioactivation and a recognized proportion of patients with high on-treatment platelet reactivity. These limitations have led clinicians to consider alternatives such as prasugrel, a more potent P2Y12 inhibitor. The authors sought to compare thromboembolic and hemorrhagic clinical outcomes after endovascular UIA treatment in patients receiving clopidogrel versus prasugrel using a large multi-institutional database.
The investigators queried the TriNetX Global Collaborative Network for adult patients with UIA who underwent endovascular treatment between 2016 and 2025 and received aspirin plus either clopidogrel or prasugrel. From an initial population of 15,496 adults identified in the database, propensity score matching was performed to generate balanced cohorts. Matching was done 1:1 using variables for demographics and comorbidities; after matching, 711 pairs (clopidogrel versus prasugrel) comprised the analytic sample used to compare outcomes.
Clinical outcomes of interest included thromboembolic events and hemorrhagic complications recorded at 6 months and at 1 year after the index endovascular procedure. Specifically reported outcomes were in-stent thrombosis, cerebral infarction, cerebral hemorrhage, and gastrointestinal hemorrhage. Results were expressed as odds ratios (ORs) with 95% confidence intervals (CIs) and associated p values. The analysis used the matched cohorts to reduce confounding by measured baseline characteristics.
At 6 months after endovascular treatment, the matched comparison showed no statistically significant differences between the clopidogrel and prasugrel groups for the prespecified outcomes:
The authors report that these findings remained nonsignificant at 1 year for the same outcomes, indicating no observed difference in the studied thromboembolic or hemorrhagic events between clopidogrel and prasugrel in the matched sample over both time horizons.
In this large propensity-matched analysis drawn from the TriNetX network, use of prasugrel as the P2Y12 agent in dual antiplatelet regimens for endovascular treatment of UIAs was not associated with a statistically significant reduction or increase in measured thromboembolic or hemorrhagic complications compared with clopidogrel at 6 months or 1 year. The authors suggest that prasugrel may be a reasonable alternative P2Y12 inhibitor for selected patients, including those with suspected or documented clopidogrel non-response. The analysis addresses a relevant clinical question given concerns about clopidogrel variability in antiplatelet effect.
Several study limitations and reporting constraints are noted or can be inferred from the source material:
The report is a preprint and has not undergone peer review; therefore the findings should be interpreted with caution and not used alone to guide practice.
The source describes propensity score matching on demographics and comorbidities but does not provide detailed breakdowns of matched covariates, absolute event counts, or balance diagnostics within this summary.
Details on antiplatelet dosing regimens, duration of therapy, procedural characteristics (device types, stent vs coil techniques), use of platelet function testing, and center- or operator-level practices were not reported in the provided abstract and may influence outcomes.
As an observational database study, residual confounding from unmeasured variables remains possible even after propensity matching.
The authors state institutional review board oversight was not required because the work used a database; they declare no competing interests. Data availability is reported as available upon request.
Within the limitations of a retrospective, propensity-matched TriNetX analysis, clopidogrel and prasugrel were not associated with significant differences in thromboembolic or hemorrhagic outcomes following endovascular treatment of UIAs at 6 months and 1 year. The authors propose prasugrel as a potential alternative P2Y12 inhibitor in selected clinical contexts, such as suspected clopidogrel non-response. This manuscript is a medRxiv preprint and has not been peer reviewed; the authors recommend careful interpretation and further confirmation in peer-reviewed studies.
Competing interests: The authors declared no competing interests.
Ethics and data: The authors state IRB approval was not required for this database research; data are available upon request according to the source report.